Join our Chief Scientific Officer, Rachael Brake as she attends this year’s RAS-Targeted Drug Development Summit, delving into the forefront of drug development targeting the Renin-Angiotensin System (RAS). We will be there to engage in insightful discussions and explore the latest trends and technologies reshaping the industry. If you’re attending, don’t miss the opportunity to connect with Rachael and share perspectives on the future of RAS-targeted therapies. Looking forward to the next three days filled of discovery, collaboration, and growth. See you there! #RASDrugDevelopment #PharmaResearch #InnovativeMedicine
Zephyr AI
Biotechnology Research
Tysons Corner, VA 4,665 followers
Harnessing Real World Data to Transform Precision Medicine
About us
Zephyr AI uses large complex data and proprietary algorithms to discover new insights and opportunities for Personalized/Precision Medicine, Drug Discovery, Drug Rescue, and Clinical Decision Support. Zephyr AI partners with leading health systems, health insurance plans, and biotechnology pioneers to improve Quality, Outcomes and Costs.
- Website
-
http://www.zephyrai.bio
External link for Zephyr AI
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Tysons Corner, VA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Tysons Corner, VA, US
Employees at Zephyr AI
Updates
-
Join us for Nephron Research LLC Healthcare Summit! We are excited to engage with fellow experts, explore cutting-edge research, and network with like-minded thought leaders who are passionate about advancing our industry. We are looking forward to the inspiring discussions and new insights that will emerge! If you’re also attending, connect with our Chief Medical Officer, Harry R. Phillips III, MD! #nephron2024 #healthcare
-
On this day, we reflect on the lives lost and the profound impact of September 11, 2001. We honor the bravery and sacrifice of those who have fought for our freedom and who continue to inspire us. Let us #NeverForget.
-
We’re headed to Barcelona, Spain! ESMO - European Society for Medical Oncology will be the perfect setting to tackle the intricacies of delivering cutting-edge cancer therapies. We’re excited for this invaluable opportunity to stay ahead of emerging trends, expand our knowledge, and foster meaningful connections within the oncology community. If you’re attending, connect with our Chief Scientific Officer, Rachael Brake. Let’s drive the future of oncology together! See you at #ESMO24 !
-
As we celebrate Labor Day, we take a moment to honor the remarkable dedication of our #team and the entire workforce that drives progress. At Zephyr AI, our #mission to advance patient treatments is fueled by the passion and hard work of our exceptional team members. Your tireless efforts are paving the way for groundbreaking discoveries. 👏 #LaborDay2024
-
Are you ready for World CDx? We are looking forward to engaging with leading experts and innovators in precision medicine and drug development. With four full days of panels and networking, this will be a fantastic opportunity to exchange ideas, explore the latest advancements, and strengthen our commitment to transforming patient care through cutting-edge solutions. If you’re attending, connect with our Senior Director of Business Development, Bill Keating! See you there! #WorldCDx #biotechnology #precisionmedicine #drugdevelopment
-
At Zephyr AI, our mission is clear: to expand the horizons of precision medicine. We champion the belief that treatments should be finely tuned to every individual. Through our cutting-edge algorithms, we sift through extensive data ranging from genomic profiles to patient records, delivering tailored insights. Our Chief Technology Officer, Jeff Sherman sits down with Virginia Business to discuss our most recent funding and how we are further pioneering advancements in #precisionmedicine. Read more about their conversation below
-
🔍 There is an urgent unmet need for improved PARPi biomarkers, particularly for patients who fail multiple lines of therapy. We’re excited by the prospect of pairing our technology with a second generation PARPi to expand the zone of sensitivity and thus the patients who can benefit from these treatments. 🧬 Join our Principal Research Scientist, Emily Vucic at American Society of Clinical Oncology (ASCO) to learn more about how we are introducing a AI-first composite biomarkers as a next generation tool for clinical development. Learn more: https://bit.ly/3x8P3FR 🔗 And feel free to explore our ASCO poster for an in-depth view of this latest research, alongside additional company information: https://bit.ly/4c0P3GS #OvarianCancer #Research #PARPInhibitors #ASCO2024
-
Remembering and honoring all those who have made the ultimate sacrifice for our country this #MemorialDay and every day. 🇺🇸